Cerecin
Cerecin is a healthcare company with more than 20 years of innovation and leadership in brain health. It develops novel evidence-based therapeutics and products targeting neurological diseases, with a focus on brain metabolism and ketogenic drug development. The company aims to create impact through medicines that treat, cure, and prevent brain diseases, and is engaged in clinical trials for Alzheimer’s disease, migraine, and infantile spasms.
Industries
Nr. of Employees
small (1-50)
Cerecin
11101 West 120th Avenue, Suite #230, Broomfield, CO 80021, United States
Patents
Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto
US-11559488-B2
View DetailsUse of genomic testing and ketogenic compounds for treatment of reduced cognitive function
US-10105338-B2
View DetailsUse of genomic testing and ketogenic compounds for treatment of reduced cognitive function
US-9175345-B2
View DetailsMonoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
US-9125881-B2
View Details
Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto
US-11559488-B2
View DetailsUse of genomic testing and ketogenic compounds for treatment of reduced cognitive function
US-10105338-B2
View DetailsUse of genomic testing and ketogenic compounds for treatment of reduced cognitive function
US-9175345-B2
View DetailsMonoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
US-9125881-B2
View DetailsProducts
Oral structured lipid therapeutic for brain energy support
An oral structured triglyceride formulation designed to increase circulating ketone bodies and support brain energy metabolism; developed for cognitive impairment and Alzheimer’s disease and evaluated in Phase II/III trials.
PET radioligand to measure ketone metabolism (diagnostic candidate)
A PET radioligand under development to quantify ketone metabolism for diagnostic and research use in neurology, cardiology and oncology.
Intravenous ketone solution for acute metabolic support
An IV beta-hydroxybutyrate formulation intended to deliver ketones directly to acute patients (e.g., traumatic brain injury, stroke, heart failure) in hospital settings.
Oral structured lipid therapeutic for brain energy support
An oral structured triglyceride formulation designed to increase circulating ketone bodies and support brain energy metabolism; developed for cognitive impairment and Alzheimer’s disease and evaluated in Phase II/III trials.
PET radioligand to measure ketone metabolism (diagnostic candidate)
A PET radioligand under development to quantify ketone metabolism for diagnostic and research use in neurology, cardiology and oncology.
Intravenous ketone solution for acute metabolic support
An IV beta-hydroxybutyrate formulation intended to deliver ketones directly to acute patients (e.g., traumatic brain injury, stroke, heart failure) in hospital settings.
Services
Management and execution of Phase II and Phase III clinical trials across multiple regions, including site selection, CRO coordination, investigator engagement and patient recruitment.
Strategic partnering, in-licensing and commercialization planning, including regional commercialization through local partners for non-drug products and co-development relationships for drug candidates.
Management and execution of Phase II and Phase III clinical trials across multiple regions, including site selection, CRO coordination, investigator engagement and patient recruitment.
Strategic partnering, in-licensing and commercialization planning, including regional commercialization through local partners for non-drug products and co-development relationships for drug candidates.
Expertise Areas
- Clinical trial management
- Neurometabolism drug development
- Lipid-based formulation and CMC
- Biomarker and molecular imaging development
Key Technologies
- Ketone-generating structured lipid therapeutics
- Intravenous beta-hydroxybutyrate delivery
- PET radioligand development for metabolic imaging
- Lipid formulation technologies
News & Updates
Cerecin announced its participation in the epilepsy congress, sharing new data on infantile spasms.
Cerecin announced new leadership appointments to strengthen its clinical and operational capabilities.
The company expanded its pipeline through a strategic acquisition to enhance its neurological treatment portfolio.
Major Korean financial institutions are investing in Cerecin as it prepares for a pre-IPO funding round.
An interview with Cerecin’s CEO Charles Stacey discussing company progress, pipeline, and strategic plans.
Cerecin’s lead asset, tricaprilin, received FDA designations for its potential in treating infantile spasms.
Cerecin announced its participation in the epilepsy congress, sharing new data on infantile spasms.
Cerecin announced new leadership appointments to strengthen its clinical and operational capabilities.
The company expanded its pipeline through a strategic acquisition to enhance its neurological treatment portfolio.
Major Korean financial institutions are investing in Cerecin as it prepares for a pre-IPO funding round.
An interview with Cerecin’s CEO Charles Stacey discussing company progress, pipeline, and strategic plans.
Cerecin’s lead asset, tricaprilin, received FDA designations for its potential in treating infantile spasms.